BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 16750359)

  • 21. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.
    Bymaster FP; Dreshfield-Ahmad LJ; Threlkeld PG; Shaw JL; Thompson L; Nelson DL; Hemrick-Luecke SK; Wong DT
    Neuropsychopharmacology; 2001 Dec; 25(6):871-80. PubMed ID: 11750180
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arylpiperazine-containing pyrrole 3-carboxamide derivatives targeting serotonin 5-HT(2A), 5-HT(2C), and the serotonin transporter as a potential antidepressant.
    Kang SY; Park EJ; Park WK; Kim HJ; Jeong D; Jung ME; Song KS; Lee SH; Seo HJ; Kim MJ; Lee M; Han HK; Son EJ; Pae AN; Kim J; Lee J
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1705-11. PubMed ID: 20149649
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dopamine D(1) and D(2) receptor agonism enhances antinociception mediated by the serotonin and noradrenaline reuptake inhibitor duloxetine in the rat formalin test.
    Munro G
    Eur J Pharmacol; 2007 Dec; 575(1-3):66-74. PubMed ID: 17725928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-Benzyl-N-(pyrrolidin-3-yl)carboxamides as a new class of selective dual serotonin/noradrenaline reuptake inhibitors.
    Wakenhut F; Fish PV; Fray MJ; Gurrell I; Mills JE; Stobie A; Whitlock GA
    Bioorg Med Chem Lett; 2008 Aug; 18(15):4308-11. PubMed ID: 18625557
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Benzothienyloxy phenylpropanamines, novel dual inhibitors of serotonin and norepinephrine reuptake.
    Boot JR; Brace G; Delatour CL; Dezutter N; Fairhurst J; Findlay J; Gallagher PT; Hoes I; Mahadevan S; Mitchell SN; Rathmell RE; Richards SJ; Simmonds RG; Wallace L; Whatton MA
    Bioorg Med Chem Lett; 2004 Nov; 14(21):5395-9. PubMed ID: 15454233
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition.
    Fish PV; Deur C; Gan X; Greene K; Hoople D; Mackenny M; Para KS; Reeves K; Ryckmans T; Stiff C; Stobie A; Wakenhut F; Whitlock GA
    Bioorg Med Chem Lett; 2008 Apr; 18(8):2562-6. PubMed ID: 18387300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
    Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Applying medicinal chemistry transformations and multiparameter optimization to guide the search for high-quality leads and candidates.
    Segall M; Champness E; Leeding C; Lilien R; Mettu R; Stevens B
    J Chem Inf Model; 2011 Nov; 51(11):2967-76. PubMed ID: 21981548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pyrrolidino-tetrahydroisoquinolines as potent dual H3 antagonist and serotonin transporter inhibitors.
    Keith JM; Gomez LA; Wolin RL; Barbier AJ; Wilson SJ; Boggs JD; Mazur C; Fraser IC; Lord B; Aluisio L; Lovenberg TW; Carruthers NI
    Bioorg Med Chem Lett; 2007 May; 17(9):2603-7. PubMed ID: 17317177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and structure-activity relationship of novel lactam-fused chroman derivatives having dual affinity at the 5-HT(1A) receptor and the serotonin transporter.
    Shen Z; Siva Ramamoorthy P; Hatzenbuhler NT; Evrard DA; Childers W; Harrison BL; Chlenov M; Hornby G; Smith DL; Sullivan KM; Schechter LE; Andree TH
    Bioorg Med Chem Lett; 2010 Jan; 20(1):222-7. PubMed ID: 19932965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity.
    Vaishnavi SN; Nemeroff CB; Plott SJ; Rao SG; Kranzler J; Owens MJ
    Biol Psychiatry; 2004 Feb; 55(3):320-2. PubMed ID: 14744476
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dual NK(1) antagonists--serotonin reuptake inhibitors as potential antidepressants. Part 2: SAR and activity of benzyloxyphenethyl piperazine derivatives.
    Ryckmans T; Berton O; Grimée R; Kogej T; Lamberty Y; Pasau P; Talaga P; Genicot C
    Bioorg Med Chem Lett; 2002 Nov; 12(21):3195-8. PubMed ID: 12372532
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors.
    Heinrich T; Böttcher H; Gericke R; Bartoszyk GD; Anzali S; Seyfried CA; Greiner HE; Van Amsterdam C
    J Med Chem; 2004 Sep; 47(19):4684-92. PubMed ID: 15341484
    [TBL] [Abstract][Full Text] [Related]  

  • 34. N-Alkyl-N-arylmethylpiperidin-4-amines: novel dual inhibitors of serotonin and norepinephrine reuptake.
    Boot JR; Boulet SL; Clark BP; Cases-Thomas MJ; Delhaye L; Diker K; Fairhurst J; Findlay J; Gallagher PT; Gilmore J; Harris JR; Masters JJ; Mitchell SN; Naik M; Simmonds RG; Smith SM; Richards SJ; Timms GH; Whatton MA; Wolfe CN; Wood VA
    Bioorg Med Chem Lett; 2006 May; 16(10):2714-8. PubMed ID: 16497500
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BDNF level in the rat prefrontal cortex increases following chronic but not acute treatment with duloxetine, a dual acting inhibitor of noradrenaline and serotonin re-uptake.
    Mannari C; Origlia N; Scatena A; Del Debbio A; Catena M; Dell'agnello G; Barraco A; Giovannini L; Dell'osso L; Domenici L; Piccinni A
    Cell Mol Neurobiol; 2008 May; 28(3):457-68. PubMed ID: 18172756
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alpha2-adrenergic receptor blockade markedly potentiates duloxetine- and fluoxetine-induced increases in noradrenaline, dopamine, and serotonin levels in the frontal cortex of freely moving rats.
    Gobert A; Rivet JM; Cistarelli L; Melon C; Millan MJ
    J Neurochem; 1997 Dec; 69(6):2616-9. PubMed ID: 9375697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Conformationally restricted homotryptamines. Part 5: 3-(trans-2-aminomethylcyclopentyl)indoles as potent selective serotonin reuptake inhibitors.
    Denhart DJ; Deskus JA; Ditta JL; Gao Q; Dalton King H; Kozlowski ES; Meng Z; LaPaglia MA; Mattson GK; Molski TF; Taber MT; Lodge NJ; Mattson RJ; Macor JE
    Bioorg Med Chem Lett; 2009 Aug; 19(15):4031-3. PubMed ID: 19560923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine.
    Thase ME; Tran PV; Wiltse C; Pangallo BA; Mallinckrodt C; Detke MJ
    J Clin Psychopharmacol; 2005 Apr; 25(2):132-40. PubMed ID: 15738744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Benzylamine histamine H(3) antagonists and serotonin reuptake inhibitors.
    Letavic MA; Stocking EM; Barbier AJ; Bonaventure P; Boggs JD; Lord B; Miller KL; Wilson SJ; Carruthers NI
    Bioorg Med Chem Lett; 2007 Sep; 17(17):4799-803. PubMed ID: 17616397
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Designing rapid onset selective serotonin re-uptake inhibitors. 2: structure-activity relationships of substituted (aryl)benzylamines.
    Middleton DS; Andrews M; Glossop P; Gymer G; Hepworth D; Jessiman A; Johnson PS; Mackenny M; Pitcher MJ; Rooker T; Stobie A; Tang K; Morgan P
    Bioorg Med Chem Lett; 2008 Jul; 18(14):4018-21. PubMed ID: 18571404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.